论文部分内容阅读
最初为降低出血危险性而开发的第二代溶栓药(血块选择性)同第一代非选择性溶栓药相比,血管再通较快而且百分率较高。为确定它们的这种作用是否部分由抑制与血块相关的纤溶酶所致,在Chandler管中研究了人全血凝结过程。将超药理学浓度的rt-PA加至浸泡已结成血块的基质中,反而引起了血块溶解不良,同时有相应的血块相关纤溶酶原依赖性缺失(Western blot ana-lysis)。相反,对血浆补充纤溶酶原(0.27mg/ml),使血浆和血块相关纤溶酶原均得到明显保存(P≤0.05,n=4)并防止了血块溶解
The second generation of thrombolytic drugs (clot-selective) originally developed to reduce the risk of bleeding had a faster and higher percentage of recanalizations than the first generation of nonselective thrombolytic drugs. To determine whether their effect is partly due to inhibition of clot-associated plasmin, the human whole blood clotting process was investigated in a Chandler tube. The addition of rt-PA at an excess of pharmacological concentration to a substrate that has clotted blood clots, on the contrary, causes poor clot lysis with a corresponding clot-associated loss of plasminogen (ana-lysis). In contrast, plasma plasminogen (0.27 mg / ml) was supplemented with significant plasma and clot-associated plasminogen (P <0.05, n = 4) and prevented clot lysis